A new publication in The New England Journal of Medicine provides more detail about the first person with type 1 diabetes (T1D) treated with Sana Biotechnology’s gene-edited islets. This person is still making insulin 14+ months after their islet transplant—without immunosuppressants! This exciting news shows the promise of cell therapies, including strategies being pursued by Breakthrough T1D and the T1D Fund. Swipe to learn more, and visit the link below to dig deeper! bit.ly/4wG0AFU